文献速递前列腺癌

小细胞前列腺癌患者的临床特征与治疗:基于肿瘤学数据库的真实世界队列分析

Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-11-21

本研究从美国肿瘤学数据库 CancerLinQ Discovery® 中筛选出 2010–2023 年间接受系统治疗的 74 例小细胞前列腺癌(SCPC)患者,评估其临床特征、一线治疗及生存结局。多数患者诊断时已有转移(45 例,60.8%),中位 PSA 为 2.8 ng/dL;一线最常见为铂类联合依托泊苷(62 例,83.8%),其中卡铂联合依托泊苷最常见(42 例,56.8%)。转移性 SCPC 患者中位总生存期为 8.3 个月,顺铂联合依托泊苷组生存优于卡铂联合依托泊苷组(比值比 3.15,95%CI 1.57–6.30;P=0.001)。

要点

  • 74 例 SCPC 患者中 45 例(60.8%)诊断时已有转移,中位 PSA 为 2.8 ng/dL。
  • 一线铂类联合依托泊苷占 83.8%(62 例),其中卡铂联合依托泊苷占 56.8%(42 例)。
  • 转移性 SCPC 中位总生存期 8.3 个月;顺铂联合依托泊苷组生存优于卡铂联合依托泊苷组(比值比 3.15,95%CI 1.57–6.30;P=0.001)。

核心结论

  • 本真实世界数据是 SCPC 治疗的最大描述之一,目前尚缺乏关于 SCPC 最佳系统治疗的明确共识,虽然需要更多研究,但真实世界实践模式可作为考虑该罕见病治疗方式时的参考。

研究设计与样本

  • 回顾性研究,从基于美国 60 余家肿瘤内科机构电子健康记录的脱敏临床数据库 CancerLinQ Discovery® 中筛选以小细胞癌组织学编码诊断的 SCPC 患者。
  • 共纳入 2010–2023 年间接受系统治疗的 74 例 SCPC 患者。
  • 主要结局为诊断 SCPC 后 1 年内的一线系统治疗。

主要发现

  • 74 例患者中 45 例(60.8%)有转移性疾病记录,诊断 SCPC 时中位 PSA 为 2.8 ng/dL。
  • 一线系统治疗中铂类化疗联合依托泊苷最常见(62 例,83.8%),卡铂联合依托泊苷为最常见方案(42 例,56.8%)。
  • 转移性 SCPC 患者中位总生存期为 8.3 个月。
  • 接受顺铂联合依托泊苷治疗的患者生存优于接受卡铂联合依托泊苷者(比值比 3.15,95%CI 1.57–6.30;P=0.001)。
  • 45.9% 的 SCPC 患者接受了二线系统治疗,二线方案高度多样。

关键数值与推荐

  • SCPC 诊断依据为小细胞癌的肿瘤组织学编码。
  • 一线系统治疗定义为诊断 SCPC 后 1 年内接受的系统治疗。
  • 顺铂联合依托泊苷 vs 卡铂联合依托泊苷的生存比较:比值比 3.15,95%CI 1.57–6.30;P=0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Small cell prostate cancer (SCPC) is a rare, aggressive disease with limited clinical data to guide treatment. In this retrospective study, we evaluated clinical, treatment, and outcomes data for patients with SCPC. METHODS: Patients with SCPC were selected from CancerLinQ Discovery®, a United States-based de-identified clinical database derived from the electronic health records of over 60 medical oncology organizations. A diagnosis of SCPC was made based on a tumor histology code of small cell carcinoma. The primary outcome of this study was assessing first-line systemic therapy within 1 year of diagnosis of SCPC. RESULTS: 74 patients with SCPC who received systemic therapy between 2010-2023 were identified. The majority had documented metastatic disease (45 patients, 60.8%) and a low PSA (median 2.8 ng/dL) at SCPC diagnosis. Platinum chemotherapy plus etoposide was the most common systemic treatment (62, 83.8%) and carboplatin plus etoposide was the most common regimen (42, 56.8%) used in the first line. Median overall survival (OS) was 8.3 months for patients with metastatic SCPC. Patients treated with cisplatin plus etoposide had improved survival versus those receiving carboplatin plus etoposide (odds ratio 3.15, 95% CI 1.57-6.30; p = 0.001). 45.9% of patients with SCPC received second-line systemic therapies, which were highly varied. CONCLUSIONS: This contemporary real-world data represent one of the largest descriptions of the treatment of SCPC. Clear consensus on the optimal systemic therapy for SCPC is lacking. While additional research is needed, real-world practice patterns can serve as a resource when considering a treatment approach for this rare disease.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Eule CJ, Warren A, Molina Kuna E, et al. Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database. Prostate Cancer Prostatic Dis. 2024. PMID: 39572637. doi:10.1038/s41391-024-00914-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。